A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood

Biology of Blood and Marrow Transplantation

Volumn 2, Issue 2, 1996, Pages 68-75

  Klingemann, Hans Georg ^a,b   Wong, Elaine ^a   Maki, Guitta ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Immunotherapy; Leukemia; NK cells; Purging; Residual disease

Indexed keywords

ARTICLE; CELL CULTURE; CELL SEPARATION; CYTOTOXICITY; HUMAN; IMMUNOLOGY; LEUKEMIA; METHODOLOGY; NATURAL KILLER CELL; PATHOLOGY;

CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; TUMOR CELLS, CULTURED;

EID: 0030133617     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ible JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341:85, 1993.
2. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Ziraan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990.
3. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F, Cummings G, Sensenbrenner LL: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050, 1994.
4. Treleaven JG, Kemshead JT: Removal of tumor cells from bone marrow: an evaluation of the available techniques. Hematol Oncol 3:65, 1985.
5. Jansen J, Falkenburg JHF, Stefan DE, LeBien TW: Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies. Semin Hematol 21:164, 1984.
6. Uckun FM, Kersey JH, Haake R, Weisdorf D, Rajnsay NKC: Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3-hydroperoxycyclophosphamide) for ex vivo bone marrow purging. Blood 79:1094, 1992.
7. Yeager AM, Kaizer H, Santas GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH, Fuller DJ, Davis JM, Karp JE, May WS, Rowley SD, Sensenbrenner LL, Vogelsang GB, Wingard JR: Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 315:141, 1986.
8. Gulati S, Acaba L, Yabalom J, Reich L, Motzer R, Crown J, Doherty M, Clarkson B, Berman E, Atzpon J, Andreeff M, Gee T: Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. Bone Marrow Transplant 10:129, 1992.
9. Klingemann H-G, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepberd JD, Sutherland HJ, Phillips GL: Trans-plantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 14:389, 1994.
10. Ratanatharathorn V, Karanes C, Uberti J, Lum LG, Abella E, Dan ME, Hussein M, Sensenbrenner LL: Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant 13:625, 1994.
11. Benyunes MC, Masstimoto C, York A, Higuchi CM, Buckner CD, Thompson JA, Petersen FB, Fefer A: Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12:159, 1993.
12. Klingemann H-G, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, Reece DE, Shepherd JD, Phillips GL: Treatment with recombinant interferon (lal-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 78:3306, 1991.
13. Klingemann H-G, Deal H, Reid D, Eaves CJ: Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 21:1263, 1993.
14. Wang EK, Eaves C, Klingemann H-G: Comparison of NK-activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12. Bone Marrow Transplant 18:63, 1996.
15. Long GS, Hiserodt JC, Harnaba JB, Cramer DV: Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation. Transplantation 46:433, 1988.
16. Zhou S, Mao N, Zhang MW, Li XS, Jiang FZ, Du DL: Purging of bone marrow contaminated with a myeloid leukemia cell line by interleukin-2 and lymphokine activated killer cells. Proc Am Assoc Cancer Res 34:469, 1993. [abstract]
17. Schmidt-Wolf IGH, Negrin RS, Kiem HP, Blume KG, Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139, 1991.
18. Gambacorti-Passerini C, Rivoltini L, Fizzotti M, Rodoleo M, Sensi ML, Castelli C, Orazi A, Polli N, Bregni M, Siena S, Borin L, Poglinni E, Corneo GM, Parmiani G: Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells. Br J Haematol 78:197, 1991.
19. Ades EW, Peacocke N, Sabio H: Lymphokine-activated killer cell lysis of human neuroblastoma cells: a model for purging tumor cells from bone marrow. Clin Immunol Immunopathol 46:150, 1988.
20. Gong J, Maki G, Klingemann H-G: Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652, 1994.
21. Cbang H, Blondal JA, Benchimol S, Minden MD, Messner HA: p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk Lymphoma 19:165, 1995.
22. Klingemann H-G, Wang E: InterIeukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells. Cancer Immunol Immunother 33:395, 1991.
23. Klingemann H-G, Gong H, Maki G, Horsimn DE, Dalal BI, Phillips GL: Establishment and characterization of a human leukemic cell line (SR-91) with features suggestive of early hematopoietic progenitor cell origin. Leuk Lymphoma 12:463, 1994.
24. Cashman JD, Eaves AC, Raines EW, Ross R, Eaves CJ: Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β. Blood 75:96, 1990.
25. Gorin NC, Labopin M, Meloni G, Korbling M, Carella A, Herve P, Burnett A, Rizzoli V, Alessandrino EP, Bjorkstrand B, Ferrant A, Lowenberg B, Coser P, Simonsson B, Helbig IV, Brunet Mauri S, Verdonck LF, Iriondo A, Polli E, Colombat P, Franklin IM, Souillet G, Willamze R: Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 5:896, 1991.
26. Korbling M, Fliedner TM, Holle R, Magrin S, Baumann M, Holdermann E, Eberhardt K: Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic cell survival. Bone Marrow Transplant 7:343, 1991.
27. Osbimi K, Osbimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H: Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68:938, 1986.
28. Lotzova E, Savary CA, Herberman RB: Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol 138:2718, 1987.
29. Gibson FM, Malkovska V, Myint AA, Meager A, Gordon-Smith EC: Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products. Exp Hematol 19:659, 1991.
30. Aguila HL, Weissman IL: Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells. Blood 87:1225, 1996.
31. van den Brink MRM, Voogt PJ, Marjit WAF, van Luxemburg-Heys SAP, van Rood JJ, Brand A: Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 74:354, 1989.
32. Cesano A, Pierson G, Visonneau S, Migliaccio AR, Santoli D: Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets. Blood 87:393, 1996.
33. Yan Y, Fernandez JM, McGuirk J, Diaz-Barrientos T, O'Reilly RJ: Tumoricidal capacity of a T-cell clone and two natural killer cell clones towards human leukemic cell lines and primary leukemias. J Hematother 4:210, 1995. [abstract]
34. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet J, Long EO: Recruitment of tyrosine phosphatase HCP by the killer cell inhibitory receptor. Immunity 4:77, 1996.